AI models are commoditized, but the ecosystem of tools, services, and compliance standards is increasingly complex. The example of needing nine Azure services for only 39% NIST compliance highlights this. Companies offering a consolidated, simplified path to value will hold a significant competitive advantage.

OpenAI's Pentagon deal is only a single-digit-million-dollar contract, a tiny fraction of its projected revenue. The true value is not financial but strategic: a government contract serves as a powerful security and compliance endorsement, making hesitant enterprise buyers more comfortable adopting its AI tools.

WorkOS CEO Michael Grinich observes that AI products inherently touch sensitive corporate data, forcing them to become 'enterprise-ready' in their first or second year. This is a much faster timeline than traditional SaaS companies, which often took over five years to move upmarket.

The high cost of bringing an AI model to market ($5-10M) limits adoption to elite hospitals. By reducing validation costs 100x (to $50-100k), innovators can lower prices, making AI accessible to all hospitals and creating a viable ROI.

Adopting AI in the enterprise requires solving two distinct problems. The first is data security from external threats, addressed by certifications like FedRAMP. The second, and separate, issue is internal control: ensuring AI agents have the right permissions and guardrails to prevent them from "going rogue."

While AI and modern tools are making software development significantly cheaper, government contracting models have not adapted. Agencies remain locked into expensive, outdated procurement processes, paying more for software even as its actual cost plummets.

MedTech AI companies can speed up regulatory approval by building a trusted, real-time post-market surveillance system. This shifts the burden of proof from pre-market studies to continuous real-world evidence, giving regulators the confidence to approve innovations faster, turning them from blockers into partners.

Pharmaceutical giants are adopting AI not for moonshot "cure cancer" prompts, but to streamline critical, error-prone processes like compiling 10,000-page FDA documents. This mundane application prevents costly delays and accelerates time-to-market for multi-billion dollar drugs.

Standalone AI tools often lack enterprise-grade compliance like HIPAA and GDPR. A central orchestration platform provides a crucial layer for access control, observability, and compliance management, protecting the business from risks associated with passing sensitive data to unvetted AI services.